Remove Clinical Research Remove Pharmaceuticals Remove Trials
article thumbnail

The AI model that is changing clinical trial design

Drug Target Review

Clinical trials are expensive, slow and often limited by outdated design constraints. They offer patient-specific outcome predictions, generated using machine learning models trained on real historical clinical data. Digital twins offer a way forward. Unlearn is one of the few companies applying this approach at scale.

article thumbnail

The Growing Trend of Patient-Led Clinical Research in Rare Disease

Conversations in Drug Development Trends

By: Juliane Mills, Senior Director, Therapeutic Strategy Lead, Rare Disease The rise of patient-led clinical research, particularly in rare disease, represents a significant shift in the clinical trial landscape. Why Is There an Increase in Patient-Led Rare Disease Research?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Advancing and Safeguarding Clinical Research for a Better Tomorrow

Advarra

Institutional review boards (IRBs) play a crucial role in the ever-evolving field of clinical research. Innovations in fields such as immunotherapy, cancer and chronic diseases owe their existence to clinical trials, which judiciously test and evaluate safety and efficacy.

article thumbnail

Clinical Research Organizations: Importance, Services, Selection Process and Future.

ProRelix Research

Clinical Research Organizations (CROs) are companies that provide support to the pharmaceutical and biotech industries by managing various aspects of the drug development process and conducting clinical trials. appeared first on ProRelix Research.

article thumbnail

2025: Perspectives and Predictions From Advarra Thought Leaders

Advarra

2024 has been a year of growth and evolution in clinical research. These topics include perspectives on how artificial intelligence (AI) will be leveraged in clinical research, key regulatory trends shaping the industry, the movements of site consolidation, the continued challenges (and potential solutions) of study startup, and more.

article thumbnail

Redefining Acceleration of the Drug Development Journey

PPD

By accelerating timelines, anticipating challenges and alleviating bottlenecks, pharmaceutical companies and combined CDMO and CRO partners together can help ensure those potential treatments reach the patients who need them as efficiently as possible.

article thumbnail

Understanding the Impact of the New EU Artificial Intelligence Act on Clinical Research

Advarra

The EU AI Act’s implications extend into clinical research, where AI is increasingly utilized for tasks like medical image analysis, natural language process for endpoint analysis, and generating/analyzing data for synthetic control arms. Here are some key requirements for “high risk” AI systems as they relate to clinical trials.